Basiliximab

Basiliximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD25
Clinical data
Trade names Simulect
AHFS/Drugs.com Monograph
License data
Pregnancy
category
  • AU: D
  • US: B (No risk in non-human studies)
    ATC code
    Pharmacokinetic data
    Elimination half-life 7.2 days
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    ChEMBL
    Chemical and physical data
    Formula C6378H9844N1698O1997S48
    Molar mass 143801.3 g/mol
     ☒N☑Y (what is this?)  (verify)

    Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

    Uses

    Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to ciclosporin. No short-term side effects have been reported.[2]

    Mechanism of action

    Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4]

    Chemistry

    It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[3][4]

    History

    It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[4][5]

    References and notes

    1. ↑ MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
    2. ↑ A.D. Katsambas, T.M. Lotti European handbook of dermatological treatments 2nd edition, 2003, page 291, ISBN 3-540-00878-0
    3. 1 2 Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013 Jul;26(7):662-72. PMID 23279211
    4. 1 2 3 Basiliximab label
    5. ↑ Waldman, Thomas A. (2003). Immunotherapy: past, present and future. Nature Medicine 9, 269-277.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.